Vitamin K — Coagulation and Deficiency

• Molecular Mechanism of γ-Carboxylation: Vitamin K exists in two interconvertible forms—the active hydroquinone form (KH₂) and the oxidized quinone form (K). The enzyme vitamin K-dependent carboxylase (GGCX, γ-glutamyl carboxylase), located in hepatic microsomes, catalyzes the carboxylation of glutamic acid residues in the N-terminal region of factors II, VII, IX, and X, as well as proteins C and S. This enzymatic process requires KH₂ as a cofactor and generates a modified glutamic acid residue (γ-carboxyglutamic acid or Gla) that confers calcium-binding capacity. After the catalytic cycle, vitamin K is oxidized to its quinone form (K). The enzyme vitamin K epoxide reductase (VKOR) regenerates the active hydroquinone form from the quinone, completing the vitamin K cycle. Without functional γ-carboxylation, coagulation factors are synthesized but remain biologically inert because Gla residues are required for calcium-dependent binding to phospholipid membranes—the essential first step in both the intrinsic and common coagulation pathways.

• Hepatic Synthesis of Coagulation Factors: The liver is the primary site of synthesis for all vitamin K-dependent factors (factors II, VII, IX, X, and proteins C and S). Vitamin K deficiency does not decrease the quantity of these proteins produced but rather reduces their functionality by preventing proper post-translational modification. Factor VII, with the shortest half-life (4-6 hours), is depleted first in acute deficiency, explaining why PT (which measures the extrinsic pathway including factor VII) becomes prolonged before aPTT (which measures intrinsic pathway factors II, IX, X) becomes abnormal. The sequential prolongation of these tests is a key diagnostic feature. Proteins C and S are also vitamin K-dependent anticoagulants; when their synthesis is impaired relative to procoagulant factors, a paradoxical transient hypercoagulable state can occur early in warfarin therapy—clinically significant in patients with underlying thrombophilia.

• Tissue Distribution and Absorption: Vitamin K exists naturally as phylloquinone (vitamin K₁) in plants and menaquinone (vitamin K₂) produced by intestinal bacteria. Absorption occurs in the proximal small intestine via a fat-dependent, energy-requiring process; therefore, any condition impairing fat absorption compromises vitamin K uptake. The vitamin is stored primarily in hepatic mitochondria, with smaller amounts in bone, heart, and kidneys. Fat-soluble vitamin absorption requires adequate biliary function and pancreatic secretion of lipase. Disorders of bile acid synthesis (cholestasis), pancreatic insufficiency, or surgical disruption of the terminal ileum all reduce vitamin K bioavailability. Notably, the body's vitamin K stores are limited; deficiency can develop relatively rapidly (within 1-2 weeks) if intake and bacterial production are eliminated simultaneously.

• Impact of Malabsorption and Antibiotics: Intestinal bacteria synthesize substantial quantities of menaquinone (K₂), which is absorbed and contributes significantly to systemic vitamin K stores. Broad-spectrum antibiotics, particularly those with anaerobic coverage, deplete this bacterial source without necessarily affecting dietary intake. Similarly, any process disrupting intestinal flora or reducing absorptive surface area (celiac disease, Crohn's disease, short bowel syndrome) impairs both dietary phylloquinone absorption and endogenous menaquinone production. Cholestyramine and other bile acid sequestrants impair fat-soluble vitamin absorption by reducing micellar formation. Mineral oil laxatives, often used in elderly populations, directly inhibit fat-soluble vitamin absorption.

• Inadequate Dietary Intake: Pure nutritional deficiency is uncommon in developed countries given the widespread presence of phylloquinone in leafy green vegetables, vegetable oils, and cruciferous vegetables (broccoli, kale, cabbage, Brussels sprouts). However, it remains a risk factor in malnourished populations, individuals with severe restrictive diets, prolonged parenteral nutrition without vitamin K supplementation, and institutionalized elderly patients with poor oral intake. This mechanism becomes more prominent when combined with antibiotic use eliminating intestinal bacterial synthesis.

• Antibiotic-Associated Deficiency: Broad-spectrum antibiotics, particularly those with excellent anaerobic coverage (fluoroquinolones, cephalosporins, clindamycin, aminoglycosides), suppress intestinal flora responsible for vitamin K₂ synthesis. The deficiency typically develops over 2-4 weeks of antibiotic therapy, particularly in patients with concurrent dietary restriction or malabsorption. Prolonged ICU stays with multiple antibiotic courses significantly increase risk. This mechanism explains why vitamin K deficiency remains one of the most common coagulopathies in hospitalized patients despite the lack of true primary nutritional deficiency.

• Malabsorption Disorders: Any condition reducing small intestinal absorptive surface area or impairing fat absorption compromises vitamin K uptake. Celiac disease causes villous atrophy; Crohn's disease induces mucosal inflammation and strictures, with small bowel involvement particularly problematic; short bowel syndrome following extensive resection eliminates absorptive capacity; cystic fibrosis impairs pancreatic lipase secretion necessary for fat emulsification. Biliary obstruction from pancreatic cancer, choledocholithiasis, or primary biliary cirrhosis prevents adequate bile acid delivery required for micelle formation and vitamin K solubilization. Any form of steatorrhea—including pancreatic insufficiency and primary biliary cholangitis—parallels vitamin K malabsorption.

• Warfarin and Other Vitamin K Antagonists: Warfarin inhibits vitamin K epoxide reductase, preventing regeneration of the active hydroquinone form and disrupting the vitamin K cycle. This is pharmacological antagonism rather than true deficiency but produces an identical laboratory pattern of coagulopathy. Warfarin-induced deficiency is dose-dependent and reversible with vitamin K administration or interruption of therapy. Patients on warfarin who develop vitamin K deficiency (whether from concurrent antibiotic use, malabsorption, or dietary changes) face particularly severe coagulopathy. Direct oral anticoagulants (DOACs) do not inhibit vitamin K-dependent factor synthesis and thus do not produce laboratory patterns of vitamin K deficiency, making this distinction important clinically.

• Liver Disease and Synthetic Dysfunction: While technically a synthesis problem rather than a vitamin K deficiency, advanced liver disease produces a similar pattern of prolonged PT/INR with normal or mildly elevated aPTT and normal fibrinogen. Distinguishing primary vitamin K deficiency from hepatic synthetic dysfunction relies on the response to vitamin K administration: true deficiency corrects PT/INR within 12-24 hours, whereas hepatic dysfunction does not. Patients with cirrhosis often have multiple mechanisms—malabsorption from portal hypertension and splenomegaly, cholestasis reducing bile acid delivery, antibiotic use for spontaneous bacterial peritonitis prophylaxis, and diminished hepatic synthetic capacity.

• Neonatal Vitamin K Deficiency: Newborns have sterile intestines and are born with minimal vitamin K stores. Breast milk contains low vitamin K (1.5 µg/L) compared to formula (60 µg/L), placing exclusively breast-fed infants at higher risk. Hemorrhagic disease of the newborn (HDN) occurs at 1-7 days of life (early), 1-3 months (classic), or after 6 months (late form) depending on vitamin K prophylaxis. Late HDN, now rare with universal prophylaxis, occurs predominantly in unvaccinated or exclusively breast-fed infants with malabsorption. Vitamin K prophylaxis at birth has dramatically reduced this once-significant cause of neonatal hemorrhage.

• Bleeding Manifestations: The bleeding pattern in vitamin K deficiency is characteristic of a coagulation factor deficiency rather than platelet dysfunction or vascular disease. Patients present with mucosal bleeding (epistaxis, gum bleeding, menorrhagia), easy bruising (ecchymosis with minor trauma), hematochezia or melena from gastrointestinal hemorrhage, and hematuria. Typically, bleeding occurs with minimal or no trauma; severity correlates with the degree of PT prolongation. Unlike platelet disorders, patients do not experience petechial rashes (which indicate thrombocytopenia) or bleeding from puncture sites alone. In severe deficiency or with concurrent elevation of prothrombin time (INR >4), spontaneous bleeding may occur, including intracranial hemorrhage—the most life-threatening manifestation—hemothorax, retroperitoneal hemorrhage, or intramuscular hematomas. The onset of bleeding varies with the underlying cause; acute presentations occur with warfarin overdose or acute illness with antibiotics, while subacute presentations develop over weeks with malabsorption.

• Severity-Related Presentations: Mild deficiency (PT 1.2-1.5× control, INR 1.2-2.0) may be asymptomatic or present only with minimal bleeding after trauma or dental procedures. Moderate deficiency (PT 1.5-3× control, INR 2.0-4.0) presents with spontaneous bleeding from mucous membranes and excessive bleeding with minor trauma. Severe deficiency (PT >3× control, INR >4.0) frequently manifests with spontaneous hemorrhage into vital organs. In hospitalized patients, vitamin K deficiency often presents with unexpected severe bleeding during diagnostic procedures (paracentesis, thoracentesis, line placement) or with clinical deterioration from occult gastrointestinal bleeding.

• Physical Examination Findings: Examination typically reveals petechiae and ecchymoses in various stages of healing, concentrated in dependent areas and sites of trauma. Gingival bleeding and bleeding at tooth extraction sites are common. The absence of splinter hemorrhages and Osler nodes helps exclude bacterial endocarditis. Patients may have signs of the underlying etiology: jaundice and ascites (if liver disease or cholestasis), abdominal distension with rebound tenderness (if retroperitoneal hemorrhage), focal neurologic deficits (if intracranial hemorrhage), or a distended abdomen with signs of volume depletion (if massive gastrointestinal bleeding). Lymphadenopathy and hepatosplenomegaly are absent unless the deficiency is secondary to malignancy or infection.

• Clinical Variants and Special Presentations: Warfarin-associated coagulopathy presents acutely with INR elevation (often >4) occurring within 24-72 hours of overdose or initiation at high doses. Antibiotic-associated deficiency develops insidiously over 2-4 weeks in ICU patients, often unmasked when minor procedures are attempted or with progression to spontaneous bleeding. Neonatal hemorrhagic disease presents with bleeding from umbilical stump, cephalohematoma, melena, or catastrophic intracranial hemorrhage if unrecognized. Post-operative bleeding in vitamin K-deficient patients may manifest as uncontrolled oozing from surgical sites despite correction of platelet dysfunction and fibrinogen. In cholestatic jaundice, coagulopathy coexists with hyperbilirubinemia and may be the first indication of obstruction requiring intervention.

• Coagulation Studies—Pattern Recognition: The prothrombin time (PT/INR) is typically the first test to become abnormal because factor VII, which is measured in the PT, has the shortest half-life (4-6 hours) among vitamin K-dependent factors. With progressive deficiency, the activated partial thromboplastin time (aPTT) becomes prolonged as factors II, IX, and X become depleted. The thrombin time and platelet count are normal, and fibrinogen is normal or elevated. This pattern—elevated PT/INR and aPTT with normal fibrinogen and normal bleeding time—is pathognomonic for factor deficiency (vitamin K-dependent or otherwise). The prothrombin time corrects proportionally with the degree of deficiency; an INR >2.0 in a patient on no anticoagulation suggests significant deficiency. Serial testing showing progressive prolongation supports an ongoing process (antibiotic use, worsening malabsorption) rather than a single acute event.

• Response to Vitamin K Administration: The gold standard diagnostic test is the clinical and laboratory response to vitamin K replacement. Intravenous or subcutaneous administration of phytonadione (vitamin K₁) at 10 mg produces correction of PT/INR within 12-24 hours if true vitamin K deficiency exists; correction by >50% within 24 hours strongly supports the diagnosis. In contrast, INR elevation from hepatic synthesis failure does not correct with vitamin K despite normal vitamin K stores. This distinction is critical: a patient with cirrhosis and an elevated INR will not improve with vitamin K, whereas a malnourished patient with the same INR will correct rapidly. In the acute setting, testing can proceed simultaneously with vitamin K administration given the low risk of intervention; waiting for vitamin K response should never delay treatment of life-threatening hemorrhage.

• Laboratory Tests for Etiology Determination: Once vitamin K deficiency is established, investigation of the underlying cause guides long-term management. Prealbumin and albumin assess nutritional status; total bilirubin, alkaline phosphatase, and transaminases evaluate for cholestasis or hepatic disease. Prothrombin time ratio (PT patient/PT control) may show vitamin K responsiveness. Fecal fat quantifies steatorrhea if malabsorption is suspected. Celiac serologies (tissue transglutaminase IgA) identify celiac disease. International normalized ratio (INR) calculated from PT standardizes reporting across institutions and is superior to PT ratio, particularly for warfarin monitoring. Plasma prothrombin time may be prolonged disproportionately to aPTT if factor VII is predominantly affected, as occurs early in deficiency or warfarin use.

• Imaging for Hemorrhage Assessment: While not diagnostic for vitamin K deficiency, imaging is essential once bleeding is documented. CT imaging of the head is mandatory if neurologic symptoms are present given the catastrophic consequences of intracranial hemorrhage. Chest X-ray identifies hemothorax. Abdominal imaging (CT or ultrasound) assesses for retroperitoneal hematoma or occult gastrointestinal bleeding. Upper endoscopy is indicated for hematemesis or melena to identify the bleeding source and permit hemostasis, typically after correction of coagulopathy with vitamin K and potentially fresh frozen plasma or prothrombin complex concentrate (PCC) if bleeding is life-threatening.

• Differential Diagnosis Considerations: Several conditions mimic vitamin K deficiency on initial laboratory testing. Disseminated intravascular coagulation (DIC) produces elevated PT and aPTT but with low platelets and decreased fibrinogen—distinguishing features absent in vitamin K deficiency. Common pathway factor deficiencies (factors I, II, V, X, fibrinogen) produce elevated PT and aPTT; specific factor assays differentiate multiple deficiencies (vitamin K-dependent: factors II, VII, IX, X) from single factor def

Immediate stabilisation (life-threatening or intracranial bleeding)

• Hold the offending agent and resuscitate: stop warfarin, secure airway/access, transfuse red cells for hemodynamic instability, and obtain emergent head CT if any neurologic sign is present.
• Four-factor prothrombin complex concentrate (4F-PCC, e.g., Kcentra): replaces factors II, VII, IX, X immediately. ASH and AHA/ASA (spontaneous intracerebral hemorrhage guidance) favor 4F-PCC over fresh frozen plasma for vitamin K antagonist–associated major bleeding because it corrects INR in minutes with a fraction of the volume. Dosing is weight- and INR-based.
• Intravenous phytonadione (vitamin K₁) 10 mg, given by slow infusion: always co-administered with PCC. PCC has a short functional life; without vitamin K, γ-carboxylation remains blocked and the INR rebounds within hours. Onset of vitamin K effect is 12–24 hours, not immediate — it is never monotherapy for active hemorrhage.
• Fresh frozen plasma: acceptable only when PCC is unavailable; limited by volume, thawing delay, and transfusion reactions.

Non-emergent correction

• Oral phytonadione: preferred over subcutaneous dosing, which absorbs erratically in hypoperfused or edematous patients. For a supratherapeutic INR without bleeding, ACCP/CHEST antithrombotic guidance and ASH recommend simply withholding warfarin and monitoring for most patients rather than reflexively giving vitamin K.
• Parenteral or high-dose oral replacement in malabsorption: cholestasis, cystic fibrosis, short bowel, and bile-acid sequestrant use require bypassing or exceeding the impaired enteral route, plus treatment of the underlying cause (biliary decompression, pancreatic enzyme replacement, gluten-free diet).

Prophylaxis and definitive measures

• Neonatal prophylaxis: the AAP recommends a single intramuscular dose of vitamin K₁ (0.5–1 mg) within hours of birth for all newborns; oral regimens are inferior for preventing late hemorrhagic disease.
• Source control: endoscopic, interventional-radiologic, or surgical hemostasis after coagulopathy is corrected.

Contraindicated / avoid

• Rapid IV push of phytonadione — anaphylactoid reactions.
• Menadione (vitamin K₃) in neonates and G6PD deficiency — oxidative hemolysis and kernicterus.
• Idarucizumab or andexanet alfa — these reverse DOACs, not vitamin K antagonists.

Complications of the deficiency itself

• Intracranial hemorrhage (emergency): loss of functional factors II, VII, IX, X permits unchecked bleeding into a closed space. Signaled by headache, vomiting, altered mental status, focal deficit, or in an infant a bulging fontanelle and seizure — the classic presentation of late hemorrhagic disease of the newborn in an infant who never received prophylaxis. Immediate non-contrast head CT.
• Hemorrhagic shock from GI or retroperitoneal bleeding (emergency): melena, hematemesis, flank/psoas pain with an unexplained hemoglobin drop and tachycardia.
• Compartment syndrome from intramuscular hematoma: pain out of proportion, tense compartment, paresthesias.
• Procedure-related bleeding: uncontrolled oozing after paracentesis, thoracentesis, line placement, or dental extraction in an unrecognized deficiency.
• Reduced γ-carboxylation of osteocalcin and matrix Gla protein: chronic deficiency is linked to impaired bone mineralization and vascular calcification; a mechanism-level association rather than an acute finding.

Complications of treatment

• Anaphylactoid reaction to intravenous phytonadione (emergency): hypotension, flushing, bronchospasm, cardiovascular collapse, attributed to the solubilizing vehicle and rapid infusion — hence slow administration.
• Warfarin resistance after high-dose vitamin K: repletion of hepatic stores makes re-anticoagulation difficult for up to a week; a real problem in mechanical valve patients, who are then bridged with heparin.
• Thromboembolism after reversal: PCC contains procoagulant factors and reversal removes the indication-driven anticoagulation; watch for stroke, valve thrombosis, or VTE.
• Volume overload (TACO), TRALI, and transfusion reactions with FFP: rising oxygen requirement and pulmonary edema after large-volume plasma.
• Warfarin-induced skin necrosis: protein C (half-life comparable to factor VII) falls before factors II, IX, X, producing transient hypercoagulability with dermal microvascular thrombosis in fat-rich areas — breast, thigh, buttock — days after starting warfarin without heparin overlap, classically in protein C deficiency.
• Menadione-induced hemolysis and kernicterus in neonates and G6PD deficiency.

• PT prolongs before aPTT: factor VII has the shortest half-life (4–6 hours). An isolated elevated PT/INR with normal platelets and normal fibrinogen in a hospitalized, poorly fed patient on broad-spectrum antibiotics is vitamin K deficiency until proven otherwise.
• Best next step for asymptomatic prolonged INR from deficiency: hold the offending drug and give oral phytonadione. Best next step for the same patient with intracranial hemorrhage: 4F-PCC plus IV vitamin K together — vitamin K alone is far too slow, PCC alone wears off.
• The vitamin K trial is diagnostic: correction of INR within 12–24 hours confirms deficiency; failure to correct points to hepatic synthetic failure, where factor V (not vitamin K–dependent) is also low. Factor V distinguishes liver disease from pure vitamin K deficiency.
• Neonatal association examiners love: exclusively breast-fed infant, home birth or parental refusal of the AAP-recommended IM vitamin K, presenting at weeks-to-months with late hemorrhagic disease of the newborn and intracranial hemorrhage. Prophylaxis is intramuscular, not oral.
• Warfarin-induced skin necrosis: protein C falls first → dermal thrombosis in fatty tissue days after initiation; underlying protein C deficiency is the classic setup, and heparin overlap is the prevention.
• Common distractor 1: DIC. It also prolongs PT and aPTT, but adds thrombocytopenia, low fibrinogen, elevated D-dimer, and schistocytes — none of which occur in vitamin K deficiency.
• Common distractor 2: reaching for idarucizumab or andexanet alfa. Those reverse DOACs; DOACs do not impair γ-carboxylation and are not reversed by vitamin K.
• Do not confuse deficiency with excess: there is no meaningful toxicity syndrome from dietary phylloquinone, but menadione (K₃) causes hemolysis and kernicterus in neonates and G6PD deficiency.